ALLO-647

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Phase 1 ALPHA and ALPHA2 trials demonstrate cemacabtagene ansegedleucel achieves 67% overall response rate and 58% complete response rate in relapsed/refractory LBCL patients using the selected Phase 2 regimen.

Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.

A phase 1 trial of ALLO-316 showed a 50% overall response rate in patients with CD70-positive renal cell carcinoma (RCC) with a tumor proportion score (TPS) of ≥50%.

Allogeneic "off-the-shelf" CAR-T cell therapies are emerging as alternatives to autologous CAR-T treatments, offering faster availability, reduced manufacturing complexity, and potentially lower costs for patients with B-cell malignancies.